Pharmaceutical Stocks Stumble, $290 Million Market Cap Vanishes in a Day

Generic and specialty drugmaker Amneal Pharmaceuticals (NASDAQ: AMRX) closed at $13 on the Nasdaq on the 7th, down 5.25%, which erased roughly $210 million in market value (about KRW 290 billion), bringing its total market capitalization to approximately $4.1 billion (around KRW 5.8 trillion). Trading volume was about 1.02 million shares.

At the same day’s annual shareholders’ meeting, all board members were re-elected and proposals on executive compensation and auditor appointments were approved, leaving the governance structure unchanged. Several directors also converted restricted stock units (RSUs) into shares, further increasing their direct ownership through insider compensation transactions.

Amneal Pharmaceuticals, headquartered in Bridgewater, New Jersey, is one of the largest generic and biosimilar drug manufacturers in the U.S. The company had bolstered growth expectations with positive interim results from its Phase 4 trial of the Parkinson’s treatment Crexont and by reaffirming its 2026 performance guidance. However, its share price has recently experienced a short-term correction amid a broader valuation reassessment.